John Cox sold $107k of DYN
CEO & President at Dyne Therapeutics, Inc.. 5,658 shares at an average of $18.88, traded Sep 8, 2026, filed Sep 8, 2026.
Score components
- +25RoleCEO
- +10Trade size$107k at market
- 0Share of holdings soldSold 1.6% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001498428-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | SOpen-market sale Common Stock10b5-1 | -5,658 | $18.88 | $107k | 357,507 | 35 d ago |
Related signals
Other insiders at Dyne Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | DYNbuy Dyne Therapeutics, Inc. | Brian S Posner director | $40k 2,500 shares | +10% | |
| 20Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $116k 5,035 shares | -3% | |
| 15Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $25k 1,085 shares | -1% | |
| 35Weak | Dyne Therapeutics, Inc. | Dirk Kersten director | $2.5M 129,672 shares | -3% | |
| 33Weak | DYNbuy Dyne Therapeutics, Inc. | Brian S Posner director | $39k 2,000 shares | +17% | |
| 40Moderate | Dyne Therapeutics, Inc. | Dirk Kersten director | $13M 688,788 shares | -13% | |
| 35Weak | DYNbuy Dyne Therapeutics, Inc. | Brian S Posner director | $45k 3,000 shares | +35% | |
| 26Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $41k 2,732 shares | -1% | |
| 10Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $13k 904 shares | -1% | |
| 10Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $2,205 148 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.